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MiceIn this work we have evaluated the gene expression proﬁle of prolactin and prolactin receptor in the pitu-
itary and the uterus of female mice with metoclopramide-induced hyperprolactinemia treated with
estrogen and/or progesterone. For this purpose, 49 Swiss female mice were allocated to seven groups.
Interventions: 50-day treatment with metoclopramide, progesterone and estrogen. Our results showed
that in the pituitary, metoclopramide-induced hyperprolactinemia increased prolactin expression. In
the castrated animals, progesterone, with or without estrogen, produced an increase in prolactin. Pitui-
tary prolactin receptor and the estrogen and progesterone treatment were responsible for the rise in
PRLR-S2. In the uterus, no differences in prolactin expression were found between the different study
groups. PRLR-S1 had its expression reduced in all castrated animals as against the castrated group treated
with vehicle. In the noncastrated animals, PRLR-S2 rose in the metoclopramide-treated group, and, in the
castrated animals, its expression diminished in all groups in relation to the vehicle-treated castrated con-
trols. An increase in PRLR-S3 was found in the oophorectomized animals treated with a combination of
estrogen and progesterone. PRLR-L rose in the oophorectomized animals treated with progesterone in
isolation or in association with estrogen. These ﬁndings suggest that metoclopramide associated to pro-
gesterone or estrogen may determine an increase in pituitary prolactin and PRLR-S2 expression. The
estrogen-progesterone may enhance the expression of PRLR-S3 and PRLR-L isoform of prolactin receptor.
 2013 Elsevier Inc. All rights reserved.1. Introduction
Hyperprolactinemia is the most common endocrine disorder
productive of hypersecretion on the hypothalamic-pituitary axis.
It occurs predominantly in young women (20–30%) and can lead
to several abnormalities, including infertility (Rossi, 2009). Hyper-
prolactinemia is characterized by high levels of prolactin (PRL) – a
simple peptide of approximately 200 amino acids – in the blood;
its biological effects are mediated by its interaction with its recep-
tor (PRLR) Rossi et al., 2002.
The PRLR belongs to the superfamily of type 1 cytokine recep-
tors (Bole-Feysot et al., 1998), and isoforms are generated by the
splicing of RNA from only one gene or through post-traductional
modiﬁcations. In mice a long isoform (PRLR-L) and three short ones
(PRLR-S1, PRLR-S2, and PRLR-S3) are known. Expression of these
isoforms may vary according to the estrous cycle, and it is also
associated with high PRL levels in the circulation (Binart et al.,
2010; Casanueva et al., 2006).In mice it is possible to mimic hyperprolactinemia symptoms
by administering metoclopramide. This drug acts on the speciﬁc
dopamine D-2 receptor antagonist in the pituitary. It binds to the
receptors, and through apoptosis inhibition in lactotrophs, it in-
creases PRL production (Gomes et al., 2009; Iwanaga et al., 2011;
Radl et al., 2011). Additionally, in the experimental metoclopra-
mide-induced model, a reduction in the synthesis of ovarian ste-
roids during the proestrous phase, as well as a decrease in
progesterone during pregnancy, has been observed (Betzold,
2004; Kinoshita et al., 2001). Histomorphometric analysis shows
endometrial growth during diestrus (Panzan et al., 2006; Rossi
et al., 2002), demonstrating the drug’s interference in the repro-
ductive system of the animals and its usefulness in studies of the
disorder in vivo.
However, the real effects of both hyperprolactinemia and hor-
mone replacement therapy on PRLR expression in the pituitary
and the uterus are still unclear (Gomes et al., 2009). It is known
that interference in the regulation of the expression of the receptor
may change PRL action in target tissues. Such knowledge could aid
in the choice of therapeutic strategies for women with hyperpro-
lactinemia-induced infertility (Casanueva et al., 2006). Thus, the
present study aims to analyze, in castrated adult female mice,
Table 1
Serum concentration of 17b estradiol, progestogen, and prolactin in the study groups.
17b estradiol-pg/mL Progestetone-ng/mL Prolactin-ng/mL
G1 138.27 ± 3.58a 14.25 ± 3.15b 61.94 ± 2.12
G2 140.98 ± 5.82a 12.96 ± 1.33b 407.50 ± 5.52c
G3 3.32 ± 0.63 1.49 ± 0.10 58.48 ± 2.59
G4 5.29 ± 1.22 1.37 ± 0.27 204.91 ± 3.58
G5 141.04 ± 7.27a 0.85 ± 0.12 203.77 ± 4.97
G6 4.49 ± 1.23 14.07 ± 1.10b 335.73 ± 13.64c
G7 139.83 ± 4.10a 16.89 ± 0.31b 304.81 ± 4.79c
a higher concentrations of estrogen when compared to the OSS, OM, and OMP
groups (p < 0.05).
b higher concentrations of progestogen when compared to the OSS, OM, and OME
groups (p < 0.05).
c higher concentrations of prolactin when compared to the OSS group (ANOVA).
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expression of PRL and its receptors in the uterus and the pituitary
as well as the effect of estrogen and/or progesterone therapy on the
same expression.
2. Materials and methods
This research was approved by the local institutional commit-
tee. Number: 0413/09.
2.1. Animals
Sixty-four virgin female Swiss mice, each aged approximately
100 days and weighing on average 30 g, were conﬁned to plastic
cages measuring 45  35  15 cm (length, width, and height,
respectively) and having metal grid covers. Food and water were
ad libitum. Room temperature was kept at 22 C and light was pro-
vided artiﬁcially with ﬂuorescent lamps (Phillips 40 W) in a photo-
periodic cycle L12:D12 with light period 7 a.m.–7 p.m.
2.2. Surgery and animal treatment
Prior to oophorectomy, all animals underwent colpocytological
exams for 3 weeks for characterization of the estrous cycle. A total
of 12 animals with irregular cycles were excluded, and 3 died fol-
lowing castration. A total of 14 animals with intact ovaries were
allocated to two groups: G1 (treated with saline solution) and G2
(treated with metoclopramide). A total of 35 oophorectomized ani-
mals was randomized (Iwanaga et al., 2011) to ﬁve subgroups of
seven animals each: G3 (treated with saline solution), G4 (treated
with metoclopramide), G5 (treated with metoclopramide + 17b-
estradiol), G6 (treated with metoclopramide + micronized proges-
terone), and G7 (treated with metoclopramide + 17b-estra-
diol + micronized progesterone).
2.3. Solution administration
The drugs and the vehicle were administered subcutaneously
using a volume of 100 lL (0.1 ml) per solution for 50 consecutive
days. The daily metoclopramide (Sigma, St Louis, MO) dose was
200 lg in 0.9% saline solution. Micronized progesterone (Sigma)
and 17b-estradiol (Sigma) were administered in oil-based solution
in daily doses of 1 lg and 1 mg, respectively (Barañao et al., 1991;
Rossi, 2009). At the end of the experimental period, one hour after
solution administration, the animals were sacriﬁced in the proe-
strous phase, except for the oophorectomized animals, which con-
tinued to receive the solutions until they entered that phase. No
animals were lost during the treatment phase.
2.4. Hormone measurements
Blood was collected for measurements of circulating concentra-
tions of serum estradiol, progesterone, and PRL by radioimmunoas-
say (Siemens, Princeton, NJ – USA). Reactions were carried out in
duplicate as previously described (Rossi et al., 2002).
2.5. Quantitative real-time polymerase chain reaction (qRT-PCR)
The uterus and the pituitary were removed and processed for
total RNA extraction using the TRIzol (Life Technologies, USA) pro-
tocol. Synthesis of cDNA was performed from 2 lg of total RNA
with the Hi Capacity Reverse Transcription Kit (Life Technologies,
USA) following the manufacturer’s instructions. The resultant
cDNAs underwent conventional PCR using a pair of speciﬁc primers
for the b-actin gene (forward – AAT TGT GGC TGA GGA CTT TG30/reverse – CAC AGA AGC AAT GCT GTC AC) to verify synthesis effec-
tiveness. Following fragment analysis in agarose gels (Invitrogen),
the cDNAs were subjected to qRT-PCR reaction. Gene expression
quantiﬁcation was conducted using a RNA mixture of brains from
normal female mice as a reference sample since they expressed
both PRL and all of its isoforms in our tests. The oligonucleotide
for ampliﬁcation were the following: PRL (forward – AAT TAG
CCA GGC CTA TCC TGA AG/reverse – GGA TGG AAG TTG TGA CCA
AAC A), PRLR (forward – AAG CCA GAC CAT GGA TAC TGG AG),
PRLR-L (reverse – AGC AGT TCT TCA GAC TTG CCC TT), PRLR-S1 (re-
verse – AAC TGG AGA ATA GAA CAC CAG AG), PRLR-S2 (reverse –
TCA AGT TGC TCT TTG TTG TGA AC), PRLR-S3 (reverse – TTG TAT
TTG CTT GGA GAG CCA GT), all designed with the Primer Express
3.0 (Applied Biosystems, Foster City, CA, USA) program and synthe-
sized by Integrated DNA Technology (DNA Technologies, Coralville,
IA, USA). Reactions were carried out in duplicate with the 7500
Real Time PCR System (Applied Biosystems, Foster City, CA, USA)
using a total volume of 25 ll with 450 nM of primers and SYBR
Green PCR Master Mix (Applied Biosystems). The b-actin gene
was selected as housekeeping gene for correction of variability.
Calculations for transcript expression were made using the Pfaﬂl
method (Pfafﬂ, 2001).
2.6. Data analysis
The data were grouped by homogeneity in each treatment
group for each speciﬁc result using the Kolmogorov–Smirnov
(KS) test. Results were analyzed using the analysis of variance test,
ANOVA, complemented by the Tukey–Kramer post hoc test
(GraphPad Prism5), and they were expressed as average and stan-
dard deviation.
3. Results
Serum concentrations of estrogen, progesterone, and prolactin
in the study groups: Estrogen concentration was higher in the
two groups of non-castrated animals (G1 and G2) and in the two
groups of animals treated with the hormone (G5 and G7). Proges-
terone also increased in G1 and G2 and in the groups of animals
treated with the hormone (G6 and G7). As for PRL, an increase in
serum level was observed in G2 and in the animals treated with
progesterone in isolation (G6) or in association with estrogen
(G7) Table 1.
3.1. Expression of PRLR and PRL in the pituitary
The PRLR in the pituitary showed that PRLR-S1, PRLR-S2, PRLR-
S3, and PRLR-L were expressed in all animals in all groups. No dif-
ferences in PRLR-S1 expression were found between the groups
(Fig. 1B). No signiﬁcant difference in PRLR-S2 expression was found
Fig. 1. Values of PRL and PRLR gene expression in relation to b-actin. (A) Pituitary PRL ⁄p < 0.05 (ANOVA) in relation to G1, G3, G4, and G5. (B) PRLR-S1. (C) PRLR-S2 ⁄p < 0.05
(ANOVA) in relation to G1, G2, G3, and G7. (D) PRLR-S3. (E) PRLR-L Groups: G1 Saline Solution/G2 Metoclopramide/G3 Oophorectomized + saline solution/G4
Oophorectomized + metoclopramide/G5 Oophorectomized + metoclopramide + 17b estradiol/G6 Oophorectomized + metoclopramide + progesterone/G7 Oophorectom-
ized + metoclopramide + 17b estradiol + progesterone. The broken line represents the mouse brain reference value.
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were no different in their expression from groups G3
(0.39 ± 0.01), G4 (0.30 ± 0.04), or G7 (0.40 ± 0.04). A larger quantity
of transcripts for PRLR-S2 was observed in the oophorectomized
animals to which the sex steroids were administered in isolation
(G5 and G6). The G5 expression of PRLR-S2 of 0.61 ± 0.14 was sig-
niﬁcantly larger than those of the G1, G2, G3, G4, and G7 groups
(p < 0.05). The G6 expression of the same isoform (0.50 ± 0.08)
was greater than that of G4 (p < 0.05) (Fig. 1C). No difference was
found between PRLR-S3 (Fig. 1D) and PRLR-L (Fig. 1E) in the ani-
mals with or without intact ovaries. A larger quantity of PRL tran-
scripts (075 ± 0.001 p < 0.005) was observed in G2, the non-
castrated animals treated with metoclopramide, when compared
to non-castrated animals treated with saline solution
(0.67 ± 0.009). Among the oophorectomized animals, the largestPRL expressions were found in groups G6 (0.77 ± 0.04) and G7
(0.76 ± 0.01) in signiﬁcantly different amounts from groups G1
(O.67 ± 0.09), G3 (0.67 ± 0.02), and G4 (0.66 ± 0.01) (p < 0.05). Also
in signiﬁcantly larger quantity was G6 expression when compared
against G5 (0.70 ± 0.02) (p < 0.05) (Fig. 1A).
3.2. Transcriptional expression of PRL and its receptors in the uterus
In this tissue, PRL expression was observed in all experimental
groups, but with no statistical differences (Fig. 2A). The four iso-
forms (PRLR-S1, PRLR-S2, PRLR-S3, and PRLR-L) were detected in
the uterus. With respect to the PRLR-S1 isoform, there was no dif-
ference between G1 (3.40 ± 2.29) and G2 (3.39 ± 2.37). However, in
the oophorectomized groups, G3 had the largest expression
(11.87 ± 6.13) (p < 0.05) (Fig. 2B). The PRLR-S2 isoform was more
Fig. 2. Values of PRL and PRLR gene expression in relation to b-actin. (A) Uterine PRL. (B) PRLR-S1 with ⁄p < 0.05 (ANOVA) compared to the other groups. (C) PRLR-S2 with
⁄p < 0.05 (ANOVA) compared to the other groups. (D) PRLR-S3, ⁄p < 0.05 (ANOVA) compared to G1, G2, G3, and G4. (L) PRLR-L, ⁄p < 0.05 (ANOVA) compared to G1, G2, G3, G4,
and G5. Groups: G1 Saline Solution/G2 Metoclopramide/G3 Oophorectomized + saline solution/G4 Oophorectomized + metoclopramide/G5 Oophorectomized + metoclo-
pramide + 17b estradiol/G6 Oophorectomized + metoclopramide + progesterone/G7 Oophorectomized + metoclopramide + 17b estradiol + progesterone. The broken line
represents the mouse brain reference value.
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the ophorectomized groups, the average expression values were
6.28 ± 3.16, 2.87 ± 1.19, 2.68 ± 0.72, 1.66 ± 1.03 and 1.17 ± 0.40, in
G3, G4, G5, G6 and G7, respectively. A statistical difference was ob-
served between two of the groups, G2 and G3, which most ex-
pressed the gene, and all of the other groups (p < 0.05) (Fig. 2C).
As regards PRLR-S3, no signiﬁcant difference was obtained be-
tween G1 (2.85 ± 1.89) and G2 (3.06 ± 1.71). Its greatest expression
was found in G7 (6.10 ± 0.11) (p < 0.05) (Fig. 2D). The PRLR-L in the
non-oophorectomized groups showed average of 1.77 ± 0.48 and
1.86 ± 0.47, respectively in G1 and G2. In the oophorectomized
groups, the expression values were 1.72 ± 0.73 (G3); 2.18 ± 0.34
(G4); 1.91 ± 0.22 (G5); 3.42 ± 0.83 (G6); and 3.10 ± 1.13 (G7). The
largest quantities of PRLR-L transcripts were found in G6 and G7,and the difference between their amounts and those of the other
groups was signiﬁcant (p < 0.05) (Fig. 2E).4. Discussion
In our study, we identiﬁed the expression of the PRL gene and
its receptors in the pituitary and the uterus of female mice. In
the pituitary of non-castrated animals treated with metoclopra-
mide, the PRL gene expression increased, but this did not happen
in the uterus. Besides, mRNA production by PRL receptors after
the hormone treatment was also different in both tissues. This phe-
nomenon had been previously identiﬁed in other studies in the lit-
erature and was conﬁrmed by our data (Brooks, 2012).
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with intact ovaries, which fact may be accounted for by the inter-
ference of some crucial (for the increase) ovarian factor or hor-
mone other than estrogen or progesterone.
In the group of castrated hyperprolactinemic animals treated
with progesterone, there was an increase of PRL transcripts when
compared to the animals treated with estrogen. These data par-
tially corroborate the literature, which shows estrogen as being
an important factor for hyperprolactinemia in female mice (Suzuki
et al., 2008). Guivarc’h-Levêque et al. (2011) observed that an in-
crease in serum progesterone and 17b estradiol concentrations
modulated the D2 messenger RNA transcription. In their study,
the sex hormones inhibited receptor activation via positive feed-
back between ovarian steroid concentration and hypothalamic
stimulus. According to the authors, in the steroid-hypothalamus
feedback, an increase in the serum level of ovarian steroids may
determine a rise in PRL production.
The progesterone relationship with the hypothalamic-pituitary
axis was also studied by Piroli et al. (2001). The authors veriﬁed the
effect of the sex steroid on galanin (PRL-releasing factor) regula-
tion; however, in an inadequate way for altering the quantity of
mRNA in PRL. Our data suggest that progesterone also increases
mRNA expression in PRL. Jöhren et al. (1997) treated oophorectom-
ized animals with progesterone and concluded that the steroid in-
creased PRL production via inhibition of pituitary receptors for
angiotensin II. Progesterone reduced the angiotensin receptor
expression in the infundibular-tuberal pathway, allowing for
greater PRL production. This mechanism would explain increased
PRL expression in the castrated animals which received progester-
one in our study.
There is some evidence of metoclopramide and progesterone
action on this very same cell signaling pathway, very likely due
to their stimulation of the Atat5A proteins, Src kinases, and phos-
phatidilinositol-3 (PI3 K)/AKT along the pathway of the Nek3-
vav2-Rac1 proteins and, in the ﬁnal phase, due to their inﬂuence
on Mapk. A combination of these factors possibly leads to an in-
crease in PRL expression in the pituitary. It is known that two
receptor classes, cytokine and kinase tyrosine, carry out signal
transduction through their intrinsic or associated protein tyrosine
kinases. All cytokines consist of a four-a-helix bundle structure
and are closely associated with a Jak protein.
Furthermore, evidence points to alteration in DOPA activity by
estrogen, which, through membrane receptors, also interferes in
DOPA synthesis and release by dopaminergic neurons (Jacobs
and D’Esposito, 2011). (Yin and Arita, 2000) observed the impor-
tance of estrogen receptors when they found that the oophorec-
tomized animals treated with 17b-estradiol developed
hyperprolactinemia due to lactotroph hyperplasia. Suzuki et al.
(2008) veriﬁed that 17b-estradiol, progesterone, or an association
of both drugs inﬂuenced PRL gene expression in the pituitary. In
this piece of work, as stated previously, progesterone action on
PRL was found to occur both in isolation and in association with
estrogen.
Likewise, the results of pituitary PRLR expression showed that
the short isoform (S2) of the prolactin receptor was more ex-
pressed than its counterpart both in the animals treated with met-
oclopramide in association with estrogen and in those treated with
metoclopramide associated with progesterone.
The signaling pathway of the PRLR short isoform has little bio-
logical action (Gofﬁn, 2002). In the pituitary, PRL links preferably to
the long form of its receptor, which is more abundant and plays a
role of greater relevance. An increase in the short isoform of the
PRL receptor would not bring about pronounced changes in PRL
secretion, for the great regulator of the PRL signaling pathways
(Stat5A, Src kinase, PI3K/AKT, Nek3-vav2-Rac1 e Mapk) is the long
isoform. Therefore, estrogen or estrogen-progestogen therapy has abearing on decreasing PRL activity in the pituitary (Bole-Feysot
et al., 1998).
Kansra et al. (2010) observed that PRLR expression was con-
trolled by a complex transcriptional regulatory system. They also
observed that 17b estradiol promoted an increase in mRNA tran-
scripts to PRLR by acting directly on the Stat5A factor. This mech-
anism was found both in the short and long form of the receptor.
In the uterus, expression of the PRLR short and long isoforms
was found in all study groups. These results differ from those de-
scribed by Rossi et al. (2009), who detected transcripts for only
the long isoform and one of the short isoforms (S1) in non-cas-
trated animals. In our study, with reference to the data on long iso-
form expression of the uterine PRLR, the group which received
progesterone and the group treated with this hormone in associa-
tion with estrogen were those which most expressed the isoform.
This result is corroborated by Binart et al. (2010), who demon-
strated the important role played by sex steroids in the control
mechanism of PRLR-L expression.
For Kinoshita et al. (2001), PRLRs are expressed in several or-
gans and their concentrations are dependent on the serum levels
of sex hormones. Uterine PRLR has been a study target in the last
two decades, but little is known about its biology in animals sub-
jected to hyperprolactinemia (Bernichtein et al., 2010;
Słuczanowska-Gła˛bowska et al., 2010). Our study indicates that
metoclopramide treatment may alter expression of PRLR-S3 and
PRLR-L in the uterus. The biological activity of such isoforms is re-
lated to an increase in the number of cell mitoses in organs con-
nected with reproduction (Brooks, 2012).
In the present study, it seems that a reduction in serum levels of
the sex steroids in oophorectomized animals stimulated expres-
sion of uterine PRLR-S1 and PRLR-S2. It is known that not only
the sex steroids but other factors as well may stimulate the PRLRs.
It is likely that even when oophorectomized, the animals continued
producing hypothalamic PRL, though in smaller quantities. The
hypothalamus markedly inhibits PRL secretion by way of the ade-
no-pituitary with DOPA secretion. There are, however, the stimu-
lating factors of the hormone, such as TRH, oxytocin, GHRH,
GnRH, vasopressin, angiotensin II, NPY, galanin, and P substance
(Freeman et al., 2000). The decrease in serum ovarian steroids
could have activated some stimulating factor of PRLR-S1 and
PRLR-S2 expression via the uterus. However, such an assumption
needs further investigation.5. Conclusions
The expression of the PRL gene and its receptors in the pituitary
and the uterus of female mice responded differently to metoclo-
pramide-induced hyperprolactinemia with or without treatment
with estrogen and/or progesterone.
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